CD274 and esophageal squamous cell carcinoma: Overall, PD‐1/PD‐L1 immunochemotherapy significantly improved long‐term survival outcomes in patients with advanced ESCC compared with chemotherapy, independent of PD‐L1 TPS status but associated with CPS status.